Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands
申请人:Neurogen Corporation.
公开号:US20010036945A1
公开(公告)日:2001-11-01
Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF
1
receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula
1
or the pharmaceutically acceptable salts thereof wherein Ar, R
1
, R
2
, R
3
, R
4
and W are various organic and inorganic substituents.
本发明涉及高度选择性的部分激动剂或拮抗剂,用于人类CRF1受体的诊断和治疗,用于治疗与压力相关的疾病,如创伤后应激障碍(PTSD),以及抑郁症,头痛和焦虑症。该化合物的式子为1,或其药学上可接受的盐,其中Ar,R1,R2,R3,R4和W是各种有机和无机取代基。